2022 has been a jam-packed year at HealthXL full of in-person events, advisory reports and new product features. Thanks to our amazing community members and advisory team, we expect 2023 to be even more informative and eventful. In this blog, we recap on our top six highlights for the year.

Over the past month, our HealthXL community members discussed new distribution channels for DTx, seeking capital for DTx products and digital health pharma partnerships, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed “How to Overcome the Blockers to DTx Adoption and Measure Success.” In this blog we’ve pulled out the top takeaways from this series.

Over the past month, our HealthXL community members discussed getting virtual care solutions into physicians and care teams workflows, scalable business models for oncology digital health solutions, and the cost of digital health solutions, among other topics.

Over the past month, our HealthXL community members discussed digital health evidence requirements, DTx label claims, and DTx - pharma collaborations, among other topics

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed HCP and patient adoption of virtual care in oncology. In this blog we’ve pulled out the top takeaways from this series.

Over the past month, our HealthXL community members discussed the value of DTx-generated RWD, DTx Reimbursement in the US-Value- Based Contracting (VBC) Basics, and Remote Patient Monitoring programs for Pharma, among other topics.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges.

Over the past month, our HealthXL community members discussed the adoption of prescription digital therapeutics (DTx), routes to market for digital health in oncology, and approaching investors with DTx, among other topics.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges

In April, HealthXL community members discussed evidence generation strategies for digital therapeutics (DTx), clinical and economic evidence for standalone DTx and non-prescription DTx (non-PDT) patient engagement, among other topics. Here's a snapshot of five expert insights from these meetings.

In our two-part HealthXL Sprint meetings, we connect senior leaders across our community to solve health challenges.

This past month, 109 of our HealthXL community members met across 12 meetings to discuss digital measures in clinical trials, clinical and economic outcomes for RMP, and DTx last mile delivery, among other topics. We’ve put together a snapshot of 5 expert insights from these meetings.

A Round-up of 5 Expert Insights from the HealthXL Community

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges.

Our meetings create a space for industry experts to connect and discuss the most current and evolving topics in the digital health space. This segment highlights key learnings and ideas cultivated by our network of payers, providers, pharmaceutical companies, health care and technology organizations